Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.
It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.
GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 25 | -4.84 Decreased by -191.57% | -0.22 Decreased by -2.10 K% |
| Nov 14, 25 | -0.83 Increased by +45.75% | -0.51 Decreased by -62.75% |
| Aug 14, 25 | -0.55 Increased by +74.62% | -0.68 Increased by +19.12% |
| May 15, 25 | -0.33 Increased by +79.88% | -0.64 Increased by +48.44% |
| Feb 21, 25 | -1.66 Increased by +24.20% | -1.55 Decreased by -7.10% |
| Nov 14, 24 | -1.53 Decreased by -2.45 K% | -2.70 Increased by +43.33% |
| Aug 14, 24 | -2.17 Decreased by -4.23 K% | -2.70 Increased by +19.74% |
| May 15, 24 | -1.64 Decreased by -16.30 K% | -2.70 Increased by +39.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -23.03 M Decreased by -510.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -3.11 M Increased by +8.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -1.43 M Increased by +61.37% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -776.00 K Increased by +65.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -3.77 M Decreased by -27.45% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.41 M Decreased by -41.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -3.71 M Decreased by -86.24% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -2.27 M Decreased by -898.24% | Decreased by N/A% Decreased by N/A% |